Table 1.

Clinical and pathological features of 26 patients with Pancreatic Ductal Adenocarcinoma treated with Gemcitabine after pancreatic resection

Age at diagnosis (years), median (Q1-Q3)	64.5 (51–73)
Gender, male/female (%male)	17/9 (65)
Smoking habit, n (%)
No	10 (48)
Yes	8 (38)
Ex	3 (14)
Missing information	5
Alcohol Use, n (%)
No	18 (95)
Yes	1 (5)
Missing information	7
Jaundice, y/n (%y)	15/11 (58)
Diabetes mellitus, y/n (%y)	9/17 (35)
Familial*, y/n (%y)	5/21 (19)
Previous Neoplasia, y/n (%y)	2/24 (8)
Preoperative serum CAE levels (ng/ml), median (Q1-Q3)	3.2 (2.0-6.0)
Preoperative serum CA 19–9 levels (U/ml), median (Q1-Q3)	200.4 (53.5-335.9)
Size (cm), median (Q1-Q3)	3 (2.4-3.5)
Tumour type, n (%)
Adenocarcinoma	22 (85)
Adenocarcinoma Mucinous	4 (15)
Tumour grading, n (%)
G1: well differentiated	5 (20)
G2: moderately differentiated	10 (40)
G3: poorly differentiated	10 (40)
Missing information	1
T: Tumour size, n (%)
T1	1 (4)
T2	2 (8)
T3	23 (88)
N: regional lymph nodes, n (%)
N0	3 (12)
N1	23 (88)
Lymph nodes ratio, median (Q1-Q3)	0.24 (0.07-0.47)
Tumour stage, n (%)
IIA	3 (12)
IIB	23 (88)
Perineural Invasion, y/n (% y)	14/12 (54)
Vascular Invasion, y/n (% y)	3/23 (12)
Margins of resection, n (%)
R0: negative resection margins	18 (69)
R1: microscopic positive resection margins	8 (31)
Postoperative serum CAE levels (ng/ml), median (Q1-Q3)	3.4 (2.0-4.5)
Postoperative serum CA 19–9 levels (U/ml), median (Q1-Q3)	10.4 (7.3-36.2)
Treatment with Gemcitabine
Nr. Cycles, median (Q1-Q3)	5 (3–7)
Nr. Cycles < 6, n (%)	10 (39)
Nr. Cycles > 6, n (%)	16 (62)
Overall Follow-up (yrs), median (Q1-Q3)	1.4 (0.9-2.3)
Disease progression Follow-up (yrs), median (Q1-Q3)	0.9 (0.6-1.3)
Mortality rate**	16/45 (35)
Disease Progression rate**	17/29 (58)

*For neoplasia or chronic pancreatitis; **Number of events/person-years (expected number of events per 100 person-years).